In PTEN-deficient prostate cancer, prostate-specific deletion of CHD1 resulted in markedly delayed tumor progression and prolonged survival, which was associated with a reduction in MDSCs and an increase in CD8+ T cells through IL-6, a key transcriptional target of CHD1. Here, CHD1 is linked to prostate carcinoma.